<DOC>
	<DOCNO>NCT02802501</DOCNO>
	<brief_summary>Tafenoquine ( TQ ) 8-aminoquinoline anti-malarial drug development single-dose treatment radical cure P.vivax malaria give standard dos chloroquine . Currently , available drug radical cure primaquine ( PQ ) require administration 14 day , result poor compliance . In Indonesia , chloroquine replace artemisinin-based combination therapy ( i.e . ACTs ) due widespread chloroquine resistance . This study evaluate efficacy safety single dose tafenoquine co-administered ACT ( i.e . DHA-PQP ) . This single-center , double-blind , double-dummy , randomize study test superiority DHA-PQP plus TQ DHA-PQP alone prevention P. vivax malaria relapse 6 month . The study conduct male Indonesian soldier diagnose P.vivax malaria return deployment malarious region Indonesia . A PQ plus DHA-PQP comparator arm include provide informal comparison standard 14 day treatment P.vivax malaria Indonesia . Subjects glucose-6-phosphate dehydrogenase deficient ( G6PD deficient ) exclude due risk acute hemolysis follow dose 8-aminoquinolines drug . Subjects recurrence P.vivax malaria study treat ACT plus PQ ( 0.5mg/kg 14 day ) , line local treatment guideline . At end 6 month follow period , subject relapse give open label PQ ( 0.5mg/kg daily 14 day ) minimize likelihood relapse study . Approximately 200 subject screen achieve 150 randomized subject . The total duration study subject 180-195 day . This study carry support registration TQ Indonesia country ACTs first line therapy .</brief_summary>
	<brief_title>Efficacy Safety Study Tafenoquine ( TQ ) Co-administered With Dihydroartemisinin-piperaquine ( DHA-PQP ) Radical Cure Plasmodium Vivax ( P. Vivax ) Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>Male subject &gt; =18 year time signing informed consent . The subject positive Giemsa smear P. vivax ( mixed infection P.falciparum acceptable ) . The subject parasite density &gt; 20 per microliter . Glucose6phosphate dehydrogenase ( G6PD ) normal use suitable qualitative assessment , example , nicotinamide adenine dinucleotide phosphate ( NADPH ) qualitative fluorescent spot test ( Trinity Biologicals , United States America ) . The subject QTcF &lt; 450 millisecond ( msec ) . Note : Reading base average triplicate ECGs obtain brief recording period machine . The subject willing able comply study protocol . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Severe P.vivax malaria define World Health Organization ( WHO ) criterion . Severe vomit ( food inability take food previous 8 hour ) . Screening hemoglobin ( Hb ) concentration &lt; 8 gram per deciliter . Liver function test ALT &gt; 2 time upper limit Normal ( ULN ) . Any clinically significant concurrent illness ( example , pneumonia , septicemia ) , significant preexisting condition ( example , renal disease , malignancy , Type 1 diabetes ) , condition may affect absorption study treatment ( example , vomit , severe diarrhea ) , clinical sign symptom severe cardiovascular disease ( example , uncontrolled congestive heart failure , severe coronary artery disease ) . History hypersensitivity , allergy adverse reaction Dihydroartemisinin ( DHA ) artemisinins , piperaquine , tafenoquine primaquine . Subject previously receive treatment tafenoquine , receive treatment investigational drug within 30 day study entry within 5 halflives , whichever longer . Subject take antimalarial ( example , ACTs , mefloquine , primaquine , quinacrine ) drug antimalarial activity within past 30 day . Subjects likely require use medication prohibit medication list take past 30 day include follow medication medication class : Drugs hemolytic potential , Drugs know prolong QT correct ( QTc ) interval include : Antiarrhythmics ; Neuroleptics antidepressive agent ; Certain antimicrobial agent , include agent follow class : macrolides , fluroquinolones imidazole triazole antifungal agent also pentamidine saquinavir ; Certain nonsedating antihistamine ; Cisapride , droperidol , domperidone , bepridil , diphemanil , probucol , levomethadyl , methadone , vinca alkaloid , arsenic trioxide . The biguanides : phenformin buformin ( exclude metformin ) . Drugs substrates renal transporter organic cation transporter 2 ( OCT2 ) , multidrug toxin extrusion protein 2 ( MATE1 ) multidrug toxin extrusion protein 2 ( MATE2 ) narrow therapeutic index ( example , antiarrhythmic agent : dofetilide , procainamide pilsicainide ) . Anticipated unable consume daily study treatment direct supervision research team . Previous participation present clinical trial , , subject experience relapse study period may enrol new subject . History illicit drug abuse heavy alcohol intake , full participation study could compromise . Any contraindication opinion Investigator DHAPQP primaquine administration : Family history sudden unexplained death ( DHAPQP ) ; Known congenital QT correct ( QTc ) prolongation ( DHAPQP ) ; Known history medical condition know prolong QT interval : example , myxoedema , cardiomyopathy , recent myocardial infarction ( DHAPQP ) ; History symptomatic cardiac arrhythmia clinically relevant bradycardia ( DHAPQP ) ; Cardiac illnesses predispose arrhythmias example , severe hypertension , leave ventricular hypertrophy , cardiomyopathy , cardiac failure reduce ejection fraction ( DHAPQP ) ; Presence electrolyte disturbance particularly hypokalemia , hypocalcemia , hypomagnesemia ( DHAPQP ) ; Rheumatoid arthritis , lupus erythematosus systemic condition may cause granulocytopenia ( primaquine ) ; History hemolytic anemia , methemoglobinemia leucopenia ( primaquine ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Artemisinin Combination Therapy</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Tafenoquine</keyword>
	<keyword>Superiority</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Radical cure</keyword>
	<keyword>Vivax</keyword>
	<keyword>ACT</keyword>
	<keyword>Plasmodium vivax malaria</keyword>
	<keyword>Dihydroartemisinin-piperaquine</keyword>
</DOC>